Sign in or create an account to add this stock to your watchlist.
About Charles River Laboratories (NYSE:CRL)
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000
Debt
Debt-to-Equity Ratio0.99
Current Ratio2.07
Quick Ratio1.78
Price-To-Earnings
Trailing P/E Ratio20.25
Forward P/E Ratio18.25
P/E Growth1.34
Sales & Book Value
Annual Sales$1.86 billion
Price / Sales2.75
Cash Flow$8.2238 per share
Price / Cash12.96
Book Value$22.11 per share
Price / Book4.82
Profitability
EPS (Most Recent Fiscal Year)$5.27
Net Income$123.35 million
Net Margins6.78%
Return on Equity24.96%
Return on Assets9.02%
Miscellaneous
Employees11,800
Outstanding Shares47,910,000
Charles River Laboratories (NYSE:CRL) Frequently Asked Questions
What is Charles River Laboratories' stock symbol?
Charles River Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories' stock buyback program work?
Charles River Laboratories announced that its Board of Directors has approved a share repurchase program on Sunday, June 4th 2017, which authorizes the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.
How were Charles River Laboratories' earnings last quarter?
Charles River Laboratories (NYSE:CRL) announced its quarterly earnings results on Thursday, May, 10th. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.26 by $0.12. The medical research company had revenue of $493.97 million for the quarter, compared to the consensus estimate of $480.03 million. Charles River Laboratories had a net margin of 6.78% and a return on equity of 24.96%. The firm's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.29 earnings per share. View Charles River Laboratories' Earnings History.
When is Charles River Laboratories' next earnings date?
What guidance has Charles River Laboratories issued on next quarter's earnings?
Charles River Laboratories updated its FY18 earnings guidance on Thursday, May, 10th. The company provided EPS guidance of $5.77-5.92 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.71. The company issued revenue guidance of $2.19-2.23 billion (+18-20%), compared to the consensus revenue estimate of $2.15 billion.
What price target have analysts set for CRL?
13 Wall Street analysts have issued 12-month target prices for Charles River Laboratories' shares. Their predictions range from $102.00 to $130.00. On average, they anticipate Charles River Laboratories' stock price to reach $115.7692 in the next year. View Analyst Ratings for Charles River Laboratories.
Are investors shorting Charles River Laboratories?
Charles River Laboratories saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 1,285,521 shares, a decrease of 39.6% from the April 13th total of 2,126,952 shares. Based on an average daily volume of 269,412 shares, the short-interest ratio is presently 4.8 days. Currently, 2.7% of the company's stock are sold short.
Who are some of Charles River Laboratories' key competitors?
Some companies that are related to Charles River Laboratories include Incyte (INCY), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Viralytics (VRACY).
Who are Charles River Laboratories' key executives?
Charles River Laboratories' management team includes the folowing people:
- Mr. James C. Foster, Chairman & CEO (Age 67)
- Dr. Davide A. Molho, Pres & COO (Age 48)
- Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 52)
- Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 57)
Has Charles River Laboratories been receiving favorable news coverage?
News stories about CRL stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Charles River Laboratories earned a daily sentiment score of 0.13 on Accern's scale. They also gave media stories about the medical research company an impact score of 47.51 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Charles River Laboratories' major shareholders?
Charles River Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.76%), Wells Fargo & Company MN (2.63%), Neuberger Berman Group LLC (1.44%), Van Berkom & Associates Inc. (1.29%), Dimensional Fund Advisors LP (1.11%) and Lord Abbett & CO. LLC (0.99%). Company insiders that own Charles River Laboratories stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, John J Crowley, Kevin Ma, Online Communications Bdirect, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories.
Which institutional investors are selling Charles River Laboratories stock?
CRL stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prudential Financial Inc., FIL Ltd, JPMorgan Chase & Co., Fisher Asset Management LLC, Hood River Capital Management LLC, Neuberger Berman Group LLC and Victory Capital Management Inc.. Company insiders that have sold Charles River Laboratories company stock in the last year include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories.
Which institutional investors are buying Charles River Laboratories stock?
CRL stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, DekaBank Deutsche Girozentrale, Massachusetts Financial Services Co. MA, BlackRock Inc., Great Lakes Advisors LLC, Russell Investments Group Ltd., Barclays PLC and Allianz Asset Management GmbH. Company insiders that have bought Charles River Laboratories stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories.
How do I buy shares of Charles River Laboratories?
Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories' stock price today?
One share of CRL stock can currently be purchased for approximately $106.71.
How big of a company is Charles River Laboratories?
Charles River Laboratories has a market capitalization of $5.08 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories employs 11,800 workers across the globe.
How can I contact Charles River Laboratories?
Charles River Laboratories' mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]
MarketBeat Community Rating for Charles River Laboratories (CRL)
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Charles River Laboratories (NYSE:CRL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Charles River Laboratories in the last 12 months. Their average twelve-month price target is $115.7692, suggesting that the stock has a possible upside of 8.62%. The high price target for CRL is $130.00 and the low price target for CRL is $102.00. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.46 | 2.46 | 2.55 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $115.7692 | $115.7692 | $117.0909 | $104.5909 |
| Price Target Upside: | 8.62% upside | 9.22% upside | 6.79% upside | 3.16% upside |
Charles River Laboratories (NYSE:CRL) Consensus Price Target History
Charles River Laboratories (NYSE:CRL) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Charles River Laboratories (NYSE:CRL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Charles River Laboratories (NYSE CRL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 97.76%
Charles River Laboratories (NYSE CRL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | George Massaro | Director | Sell | 1,218 | $107.19 | $130,557.42 | 15,055 |  |
| 5/1/2018 | David Ross Smith | Insider | Sell | 945 | $104.23 | $98,497.35 | 13,723 | |
| 3/9/2018 | George M Milne Jr | Director | Sell | 7,740 | $115.00 | $890,100.00 | 36,760 | |
| 3/6/2018 | Birgit Girshick | Insider | Sell | 9,893 | $109.10 | $1,079,326.30 | 26,470 | |
| 3/6/2018 | James C Foster | CEO | Sell | 24,008 | $110.00 | $2,640,880.00 | 325,684 | |
| 2/28/2018 | David Ross Smith | CFO | Sell | 100 | $108.43 | $10,843.00 | 13,103 | |
| 2/28/2018 | James C Foster | CEO | Sell | 3,372 | $107.39 | $362,119.08 | 324,012 | |
| 2/26/2018 | David Ross Smith | Insider | Sell | 3,868 | $107.35 | $415,229.80 | 18,483 | |
| 2/26/2018 | James C Foster | CEO | Sell | 4,800 | $106.69 | $512,112.00 | 306,914 | |
| 2/21/2018 | William D Barbo | Insider | Sell | 2,320 | $108.08 | $250,745.60 | 21,276 | |
| 2/16/2018 | David Ross Smith | Insider | Sell | 3,639 | $109.07 | $396,905.73 | 15,110 | |
| 2/15/2018 | James C Foster | Chairman | Sell | 46 | $107.50 | $4,945.00 | 292,621 | |
| 2/15/2018 | Stephen D Chubb | Director | Sell | 2,872 | $108.70 | $312,186.40 | 36,461 | |
| 1/18/2018 | Online Communications Bdirect | Director | Sell | 131,000 | $0.29 | $37,990.00 | | |
| 1/2/2018 | David Ross Smith | Insider | Sell | 5,486 | $109.53 | $600,881.58 | | |
| 1/2/2018 | James C Foster | Chairman | Sell | 4,967 | $109.44 | $543,588.48 | 329,928 | |
| 1/2/2018 | Robert J Bertolini | Director | Sell | 3,609 | $110.22 | $397,783.98 | | |
| 12/12/2017 | Kevin Ma | Director | Sell | 40,384 | $0.41 | $16,557.44 | | |
| 12/6/2017 | C Richard Reese | Director | Sell | 10,227 | $102.40 | $1,047,244.80 | 51,444 | |
| 11/10/2017 | Bradley Nixon Scharfe | Insider | Sell | 1,000,000 | $0.27 | $270,000.00 | | |
| 10/30/2017 | Bradley Nixon Scharfe | Insider | Buy | 2,500 | $0.25 | $625.00 | | |
| 10/25/2017 | Bradley Nixon Scharfe | Insider | Buy | 3,000 | $0.27 | $810.00 | | |
| 10/19/2017 | Bradley Nixon Scharfe | Insider | Buy | 2,000 | $0.29 | $580.00 | | |
| 10/17/2017 | Bradley Nixon Scharfe | Insider | Buy | 3,000 | $0.29 | $870.00 | | |
| 10/5/2017 | Davide Molho | Insider | Sell | 6,165 | $110.00 | $678,150.00 | | |
| 9/5/2017 | Davide Molho | Insider | Sell | 5,982 | $107.55 | $643,364.10 | 22,714 | |
| 8/17/2017 | William D Barbo | Insider | Sell | 4,000 | $99.91 | $399,640.00 | 20,424 | |
| 8/14/2017 | David Ross Smith | Insider | Sell | 2,552 | $67.10 | $171,239.20 | 11,671 | |
| 7/17/2017 | George Massaro | Director | Sell | 3,830 | $100.81 | $386,102.30 | 18,731 | |
| 7/10/2017 | James C Foster | Chairman | Sell | 9,516 | $98.92 | $941,322.72 | 361,171 | |
| 6/22/2017 | Davide Molho | Insider | Sell | 10,948 | $100.00 | $1,094,800.00 | 27,497 | |
| 6/22/2017 | James C Foster | Chairman | Sell | 43,154 | $100.00 | $4,315,400.00 | 361,178 | |
| 6/8/2017 | David Ross Smith | Insider | Sell | 945 | $95.00 | $89,775.00 | 14,203 | |
| 5/26/2017 | Davide Molho | Insider | Sell | 10,976 | $92.84 | $1,019,011.84 | 27,525 | |
| 5/23/2017 | Jason Wesley Scharfe | Director | Sell | 10,000 | $0.31 | $3,100.00 | | |
| 5/17/2017 | Jason Wesley Scharfe | Director | Sell | 10,000 | $0.34 | $3,400.00 | | |
| 5/12/2017 | George Massaro | Director | Sell | 1,130 | $88.30 | $99,779.00 | 15,831 | |
| 5/11/2017 | Jason Wesley Scharfe | Director | Sell | 6,000 | $0.36 | $2,160.00 | | |
| 5/10/2017 | Jason Wesley Scharfe | Director | Sell | 9,000 | $0.36 | $3,240.00 | | |
| 3/29/2017 | Jason Wesley Scharfe | Director | Sell | 10,000 | $0.34 | $3,400.00 | | |
| 3/16/2017 | Davide Molho | Insider | Sell | 11,717 | $90.00 | $1,054,530.00 | 28,266 | |
| 3/10/2017 | David P Johst | Insider | Sell | 34,593 | $89.06 | $3,080,852.58 | 201,005 | |
| 3/6/2017 | William D Barbo | Insider | Sell | 1,900 | $87.90 | $167,010.00 | 22,224 | |
| 3/3/2017 | David Ross Smith | EVP | Sell | 3,890 | $88.12 | $342,786.80 | 17,085 | |
| 3/1/2017 | Robert J Bertolini | Director | Sell | 5,255 | $87.53 | $459,970.15 | 32,140 | |
| 2/28/2017 | James C Foster | Chairman | Sell | 4,910 | $87.09 | $427,611.90 | 381,730 | |
| 2/22/2017 | James C Foster | Chairman | Sell | 9,717 | $87.64 | $851,597.88 | 388,294 | |
| 2/22/2017 | Jason Wesley Scharfe | Director | Buy | 15,000 | $0.29 | $4,350.00 | | |
| 2/21/2017 | Jason Wesley Scharfe | Director | Buy | 10,000 | $0.30 | $3,000.00 | | |
| 2/17/2017 | Jason Wesley Scharfe | Director | Buy | 10,000 | $0.30 | $3,000.00 | | |
| 2/15/2017 | Jason Wesley Scharfe | Director | Buy | 4,500 | $0.30 | $1,350.00 | | |
| 1/30/2017 | David P Johst | Insider | Sell | 13,950 | $78.00 | $1,088,100.00 | 174,696 | |
| 12/2/2016 | Stephen D Chubb | Director | Sell | 4,564 | $71.57 | $326,645.48 | 30,849 | |
| 11/28/2016 | C Richard Reese | Director | Sell | 4,539 | $71.93 | $326,490.27 | 44,943 | |
| 8/30/2016 | Davide Molho | Insider | Sell | 7,877 | $84.10 | $662,455.70 | | |
| 8/5/2016 | James C Foster | Chairman | Sell | 18,351 | $85.63 | $1,571,396.13 | 383,283 | |
| 7/29/2016 | Richard F Wallman | Director | Sell | 7,740 | $88.00 | $681,120.00 | 24,190 | |
| 7/1/2016 | George Massaro | Director | Sell | 3,740 | $83.09 | $310,756.60 | 18,935 | |
| 5/24/2016 | John J Crowley | CAO | Sell | 1,913 | $85.00 | $162,605.00 | 6,883 | |
| 5/13/2016 | Richard F Wallman | Director | Sell | 1,970 | $82.32 | $162,170.40 | 17,690 | |
| 5/10/2016 | Richard F Wallman | Director | Sell | 11,990 | $84.00 | $1,007,160.00 | 27,420 | |
| 5/9/2016 | George Massaro | Director | Sell | 985 | $82.17 | $80,937.45 | 13,020 | |
| 5/6/2016 | Richard F Wallman | Director | Sell | 2,720 | $81.00 | $220,320.00 | 15,430 | |
| 4/6/2016 | Davide Molho | VP | Sell | 30,667 | $80.00 | $2,453,360.00 | 79,008 | |
| 3/2/2016 | Nancy Gillett | VP | Sell | 7,015 | $75.00 | $526,125.00 | 23,809 | |
| 2/29/2016 | Nancy Gillett | VP | Sell | 3,646 | $73.50 | $267,981.00 | 21,953 | |
| 2/25/2016 | David P Johst | VP | Sell | 34,075 | $73.02 | $2,488,156.50 | 189,023 | |
| 2/24/2016 | James C Foster | CEO | Sell | 3,873 | $70.40 | $272,659.20 | 402,707 | |
| 2/23/2016 | George M Milne Jr | Director | Sell | 10,440 | $73.02 | $762,328.80 | 38,200 | |
| 2/22/2016 | James C Foster | CEO | Sell | 9,831 | $73.12 | $718,842.72 | 402,964 | |
| 2/12/2016 | C Richard Reese | Director | Sell | 4,228 | $71.48 | $302,217.44 | 31,123 | |
| 2/12/2016 | Nancy Gillett | VP | Sell | 6,750 | $71.90 | $485,325.00 | 25,392 | |
| 2/1/2016 | Stephen D Chubb | Director | Sell | 2,000 | $74.76 | $149,520.00 | 11,504 | |
| 12/17/2015 | George Massaro | Director | Sell | 7,740 | $80.00 | $619,200.00 | 13,120 | |
| 12/17/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $80.00 | $800,000.00 | 100,635 | |
| 11/19/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $75.00 | $750,000.00 | 100,635 | |
| 11/4/2015 | Thomas F. Ackerman | insider | Sell | 21,612 | $70.01 | $1,513,056.12 | 100,635 | |
| 11/2/2015 | Stephen D Chubb | Director | Sell | 2,000 | $66.57 | $133,140.00 | 13,504 | |
| 8/17/2015 | Thomas F Ackerman | Insider | Sell | 5,000 | $75.53 | $377,650.00 | | |
| 5/15/2015 | Thomas F Ackerman | CFO | Sell | 3,900 | $70.51 | $274,989.00 | | |
| 5/7/2015 | George Massaro | Director | Sell | 1,360 | $70.21 | $95,485.60 | | |
| 3/3/2015 | Stephen D Chubb | Director | Sell | 2,000 | $75.52 | $151,040.00 | | |
| 3/2/2015 | Deborah Turner Kochevar | Director | Sell | 2,600 | $76.59 | $199,134.00 | | |
| 3/2/2015 | James C Foster | CEO | Sell | 2,036 | $76.93 | $156,629.48 | | |
| 3/2/2015 | Nancy Gillett | VP | Sell | 4,379 | $76.72 | $335,956.88 | | |
| 2/27/2015 | Nancy Gillett | VP | Sell | 2,772 | $76.95 | $213,305.40 | | |
| 2/25/2015 | James C Foster | CEO | Sell | 4,621 | $75.96 | $351,011.16 | | |
| 2/25/2015 | Nancy Gillett | VP | Sell | 5,015 | $76.12 | $381,741.80 | | |
| 2/24/2015 | James C Foster | CEO | Sell | 4,800 | $75.70 | $363,360.00 | | |
| 2/24/2015 | Jorg Geller | VP | Sell | 12,061 | $76.17 | $918,686.37 | | |
| 2/23/2015 | James C Foster | CEO | Sell | 8,423 | $76.56 | $644,864.88 | | |
| 2/23/2015 | Jorg Geller | VP | Sell | 7,041 | $76.59 | $539,270.19 | | |
| 2/20/2015 | George M Milne Jr | Director | Sell | 6,000 | $75.87 | $455,220.00 | | |
| 2/19/2015 | James C Foster | CEO | Sell | 9,671 | $75.00 | $725,325.00 | | |
| 2/18/2015 | Stephen D Chubb | Director | Sell | 5,011 | $73.97 | $370,663.67 | | |
| 2/17/2015 | Jorg Geller | VP | Sell | 14,430 | $73.54 | $1,061,182.20 | | |
| 2/17/2015 | Thomas F Ackerman | CFO | Sell | 4,400 | $73.50 | $323,400.00 | | |
| 2/13/2015 | Davide Molho | VP | Sell | 19,075 | $74.00 | $1,411,550.00 | | |
| 2/12/2015 | Jorg Geller | VP | Sell | 8,458 | $73.68 | $623,185.44 | | |
| 1/26/2015 | Thomas F Ackerman | CFO | Sell | 10,000 | $70.00 | $700,000.00 | | |
| 1/8/2015 | David P Johst | VP | Sell | 4,737 | $67.00 | $317,379.00 | | |
| 1/7/2015 | David P Johst | VP | Sell | 26,100 | $65.00 | $1,696,500.00 | | |
| 12/1/2014 | Stephen D Chubb | Director | Sell | 2,000 | $64.44 | $128,880.00 | | |
| 11/28/2014 | David P Johst | VP | Sell | 6,982 | $65.34 | $456,203.88 | | |
| 11/17/2014 | Thomas F Ackerman | CFO | Sell | 10,000 | $63.70 | $637,000.00 | | |
| 11/14/2014 | Jorg Geller | VP | Sell | 5,610 | $63.57 | $356,627.70 | | |
| 11/6/2014 | C Richard Reese | Director | Sell | 5,849 | $63.39 | $370,768.11 | | |
| 11/4/2014 | John J Crowley | CAO | Sell | 1,000 | $64.00 | $64,000.00 | | |
| 11/3/2014 | Davide Molho | VP | Sell | 16,402 | $64.54 | $1,058,585.08 | | |
| 11/3/2014 | George Massaro | Director | Sell | 16,710 | $65.00 | $1,086,150.00 | | |
| 11/3/2014 | Thomas F Ackerman | CFO | Sell | 36,100 | $65.00 | $2,346,500.00 | | |
| 10/30/2014 | Nancy Gillett | VP | Sell | 1,069 | $65.00 | $69,485.00 | | |
| 10/28/2014 | David P Johst | VP | Sell | 74,780 | $64.00 | $4,785,920.00 | | |
| 10/3/2014 | James C Foster | CEO | Sell | 136,647 | $62.00 | $8,472,114.00 | | |
| 9/29/2014 | Thomas F Ackerman | CFO | Sell | 5,000 | $60.00 | $300,000.00 | | |
| 9/4/2014 | Davide Molho | VP | Sell | 4,900 | $61.34 | $300,566.00 | | |
| 9/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $59.18 | $118,360.00 | | |
| 8/26/2014 | George Massaro | Director | Sell | 10,440 | $60.00 | $626,400.00 | | |
| 8/18/2014 | Thomas F Ackerman | CFO | Sell | 23,156 | $59.25 | $1,371,993.00 | | |
| 8/12/2014 | Richard F Wallman | Director | Sell | 3,240 | $58.20 | $188,568.00 | | |
| 6/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $52.93 | $105,860.00 | | |
| 5/22/2014 | Deborah Turner Kochevar | Director | Sell | 3,100 | $53.30 | $165,230.00 | 11,370 | |
| 5/8/2014 | George Massaro | Director | Sell | 1,620 | $52.70 | $85,374.00 | 16,510 | |
| 5/5/2014 | Thomas Ackerman | CFO | Sell | 5,430 | $50.76 | $275,626.80 | 113,781 | |
| 3/7/2014 | Nancy Gillett | VP | Sell | 10,110 | $58.36 | $590,019.60 | 38,515 | |
| 3/4/2014 | Nancy Gillett | VP | Sell | 13,650 | $58.98 | $805,077.00 | 48,625 | |
| 3/3/2014 | Stephen Chubb | Director | Sell | 2,000 | $58.70 | $117,400.00 | 23,645 | |
| 2/28/2014 | Jorg Geller | VP | Sell | 7,486 | $59.41 | $444,743.26 | 55,722 | |
| 2/27/2014 | Nancy Gillett | VP | Sell | 4,000 | $60.00 | $240,000.00 | 43,162 | |
| 2/25/2014 | Jorg Geller | VP | Sell | 3,188 | $58.49 | $186,466.12 | 50,235 | |
| 2/20/2014 | Nancy Gillett | VP | Sell | 4,000 | $58.96 | $235,840.00 | 50,510 | |
| 2/19/2014 | Stephen Chubb | Director | Sell | 5,198 | $58.35 | $303,303.30 | 25,645 | |
| 2/18/2014 | Thomas Ackerman | CFO | Sell | 14,000 | $58.05 | $812,700.00 | 105,539 | |
| 1/13/2014 | David Johst | VP | Sell | 19,750 | $58.00 | $1,145,500.00 | 141,799 | |
| 1/7/2014 | George Massaro | Director | Sell | 5,750 | $54.00 | $310,500.00 | 15,410 | |
| 12/20/2013 | Thomas Ackerman | CFO | Sell | 5,000 | $52.72 | $263,600.00 | 107,689 | |
| 12/4/2013 | Jorg Geller | VP | Sell | 7,200 | $51.93 | $373,896.00 | 54,192 | |
| 12/2/2013 | Stephen Chubb | Director | Sell | 2,000 | $51.92 | $103,840.00 | 26,843 | |
| 9/16/2013 | George Massaro | Director | Sell | 5,958 | $47.38 | $282,290.04 | 15,410 | |
| 9/9/2013 | James C Foster | CEO | Sell | 174,479 | $47.00 | $8,200,513.00 | | |
| 9/4/2013 | Thomas F Ackerman | CFO | Sell | 6,100 | $46.13 | $281,393.00 | | |
| 9/3/2013 | Stephen Chubb | Director | Sell | 2,000 | $46.49 | $92,980.00 | 28,843 | |
| 8/29/2013 | James Foster | CEO | Sell | 40,983 | $47.00 | $1,926,201.00 | 366,580 | |
| 8/22/2013 | Davide Molho | VP | Sell | 6,500 | $47.93 | $311,545.00 | 40,892 | |
| 8/20/2013 | Stephen Chubb | Director | Sell | 4,000 | $47.46 | $189,840.00 | 30,843 | |
| 8/5/2013 | Jorg Geller | VP | Sell | 3,025 | $46.38 | $140,299.50 | 55,085 | |
| 8/5/2013 | Richard Wallman | Director | Sell | 1,500 | $45.95 | $68,925.00 | 16,700 | |
| 8/2/2013 | Davide Molho | VP | Sell | 4,100 | $45.89 | $188,149.00 | 40,892 | |
| 8/2/2013 | Deborah Turner Kochevar | Director | Sell | 4,447 | $46.02 | $204,650.94 | 13,870 | |
| 8/2/2013 | Thomas Ackerman | CFO | Sell | 26,250 | $46.03 | $1,208,287.50 | 105,039 | |
| 6/3/2013 | Thomas F Ackerman | CFO | Sell | 4,000 | $42.40 | $169,600.00 | | |
| 5/14/2013 | James C Foster | CEO | Sell | 113,810 | $45.00 | $5,121,450.00 | | |
| 5/10/2013 | George Massaro | Director | Sell | 2,020 | $44.09 | $89,061.80 | | |
| 3/13/2013 | David P Johst | VP | Sell | 17,038 | $45.00 | $766,710.00 | | |
(Data available from 1/1/2013 forward)
Charles River Laboratories (NYSE CRL) News Headlines
| Source: |
|
Charles River Laboratories (NYSE:CRL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Charles River Laboratories (NYSE:CRL) Income Statement, Balance Sheet and Cash Flow Statement
Charles River Laboratories (NYSE CRL) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
